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ABSTRACT OF THESIS
THE EFFECT OF INTRA-ARTICULAR CORTICOSTEROIDS ON THE SYSTEMIC
MESSENGER RNA RESPONSE IN AN EQUINE EXPERIMENTAL
INFLAMMATION MODEL

Intra-articular (IA) corticosteroids are regularly used in equine athletes for the control of
joint inflammation. The goal of this study was to utilize an acute synovitis inflammation
model to determine the residual effects of IA betamethasone and triamcinolone acetonide
on various inflammatory parameters and lameness.
Five mixed-breed, 2-year-old horses were randomly allocated to an IA treatment of the
radiocarpal joint with 9 mg of either betamethasone or triamcinolone acetonide. Two
weeks following treatment, horses were injected with 1μg of lipopolysaccharide (LPS)
diluted in 1 mL of 0.9% sterile saline. Following LPS injection, horses were crossed-over
and both sets of injections repeated. Lameness was subjectively scored and blood
samples were collected for mRNA analysis, as well as serum amyloid A (SAA) and
cortisol determination. Additional injections with saline-only or LPS-only were
conducted as negative and positive controls, respectively. Two-way repeated measures
analysis of variance was used to analyze all data.
Corticosteroid-only treatments results in significant mRNA expression differences, as
well as significant and prolonged serum cortisol suppression. Following LPS injection,
there was a residual treatment effect with triamcinolone evidenced by a significant
treatment effect on IL-6 and PTGS1 (cyclooxygenase-1) expression, lameness, SAA, and
cortisol concentrations, while only IL-6 expression was affected by betamethasone.
Current regulatory guidelines may be insufficient if the concern is residual antiinflammatory effects. Additionally, intra-articular corticosteroid administration is not
without risk, as evidenced by a significant and prolonged suppression of serum cortisol
concentration, and, as such, the benefits of their administration should be weighed against
those risks.
KEYWORDS: Equine, Corticosteroids, mRNA, Lipopolysaccharide, Inflammation,
Immunology
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CHAPTER 1. LITERATURE REVIEW
1.1

Joint Disease in the Horse
Lameness due to synovial joint disorders has been repeatedly reported as one of the

most common causes of wastage and reduced performance in equine athletes. Most data
have come from the Thoroughbred racing industry where epidemiological studies have
estimated that 25-30% of racehorses are affected by joint disorders [1-5], while comparable
percentages have also been seen in sport horses [6, 7]. Joint disease currently represents a
major part of the caseload for equine veterinarians as the subsequent pain and inflammation
often necessitates intervention with anti-inflammatory drugs.

1.1.1

The Equine Joint
Synovial joints make up an integral part of the musculoskeletal system and have an

intricate relationship with all other constituting elements of the system [8]. Although these
complex structures are made up of multiple important tissues that provide strength and
power for locomotion and exercise, each of these elements is susceptible to degenerative
processes. Multiple etiologies of joint disease such as infection, trauma, and progressive
degeneration can lead to a disturbance in joint homeostasis and can affect each of the
structures differently.
An important joint structure that is commonly affected is the articular cartilage.
This thin layer of hyaline cartilage covers the ends of subchondral bones that form the joint,
providing frictionless movement between the articulating bones [9]. The extracellular
matrix (ECM) of articular cartilage is primarily composed of collagen, proteoglycans, and
water, all of which contribute to maintaining homeostasis within the joint as well as
1

providing the biomechanical properties of articular cartilage. Collagen is the most abundant
macromolecule in the ECM with the principal type being fibrillar collagen type II, which
is essential for the structural integrity of cartilage [10]. Embedded in the network of type
II collagen fibers are a variety of proteoglycans that are essential for normal function [11,
12]. A major proteoglycan in articular cartilage is aggrecan, which provides osmotic
properties

that

enable

the

tissue

to

withstand

compressional

forces

[13].

Glycosaminoglycans (GAGs) are conjugated to proteoglycans like aggrecan and contribute
to cartilage’s ability to withstand compressive loading and play a role in cartilage
permeability [14]. Water content comprises 80% of the volume in cartilage and is important
for lubrication, as well as the distribution of nutrients [9]. These nutrients are controlled by
highly specialized cells called chondrocytes, which are responsible for the development,
maintenance, and repair of the ECM [10]. Destruction of articular cartilage is of great
concern as the tissue is devoid of blood vessels, nerves, and lymphatic vessels, and
therefore has a limited capacity for inherent healing and repair.
Additional basic components of a joint are subchondral bone, synovial fluid, joint
capsule, and the synovium. Subchondral bone supports the overlying cartilage, which is
integrally attached to the bone via the calcified cartilage stratum [8]. Synovial fluid is
restrained within the joint by the joint capsule. This viscous liquid is responsible for
lubrication within the joint as well as the transportation of nutrients to cartilage, which are
both largely attributed to high hyaluronan (HA) concentrations [15]. The synovium is the
connective tissue that lines the inner surface of the joint capsule [8]. It is comprised of
synoviocytes, which are believed to be responsible in the production of synovial fluid

2

components, and fibroblasts, which contribute to connective tissue formation. Combined,
these cells play a critical role in the mediation of joint inflammation and homeostasis.

1.2.2

Osteoarthritis

Equine degenerative arthritis was first described in 1938 in a publication comparing
pathological changes in equine versus human arthritis [16]. Yet, it was not until 1966 that
clinical attention of the disease and its relationship to lameness was established [17].
Articular cartilage lesions were identified as a hallmark sign of equine osteoarthritis (OA)
in 1975, however, at the time, it was recognized that there may be additional causes of
clinical disease. It is only recently that the critical importance of the synovial membrane
has received more attention.
Today, osteoarthritis is well recognized as a progressive condition that
predominantly affects diarthrodial joints and is characterized by the deterioration of
articular cartilage, changes in the subchondral bone, and soft tissues of the joint [8]. It
represents the end stage of changes that include synovitis, capsulitis, intra-articular
fractures, or ligamentous tears. These disorders are identified by the pathologic and clinical
state of a joint following single or repetitive episodes of trauma, leading to chronic pain
and decreased function. In the horse, these conditions most commonly occur in athletes but
they can affect a horse of any workload, as age-related osteoarthritic processes have been
identified in the metacarpophalangeal joints of wild horses [18].
In humans, the development of OA has been divided into two pathways: “abnormal
loading on normal cartilage and normal loading on abnormal cartilage” [19]. Similar
mechanisms are seen in horses [8]. All tissues of a joint are vulnerable to degradative
3

changes and both soft tissue inflammation and subchondral bone disease play important
roles in the OA disease process. Synovitis and capsulitis are pathobiological processes
involving inflammation in the soft tissue and have been identified as one of the most
significant factors accountable for decreased performance in race and competition horses
[2-4, 20, 21]. These conditions are results of the cyclic trauma to the synovial membrane
and fibrous joint capsule, respectively. Articular cartilage and subchondral bone can
experience injury either through direct trauma or via inflammatory mediators generated as
a result of synovitis [22].

1.2.3

Pathophysiology

The breakdown of the cartilage matrix, caused by proteolytic enzymes, results in
the proliferation of matrix macromolecule fragments within the synovial fluid, contributing
to inflammation in the synovial membrane [10]. It has been recognized that damaged
synovial membrane not only elicits pain, but also upregulates matrix catabolism mediated
via enzymes such as metalloproteinases, pro-inflammatory cytokines, and other
inflammatory mediators such as interleukin-1 (IL-1), tumor necrosis factor-α (TNFα),
prostaglandins, and free radicals [23-32].

1.2.3.1 Enzymes

In OA, it has been established that an initial histopathological alteration in cartilage
involves the depletion of collagen and aggrecan [33]. The breakdown of collagen fibrils
results in the loss of structural integrity of the tissue and loss of its biomechanical
4

properties. Alterations to biomechanical stimuli can lead to an increase in proteolytic
enzymes released by chondrocytes. Matrix metalloproteases (MMP) are a class of enzymes
that have a major role in OA disease processes due to their involvement in extracellular
matrix degradation [8]. MMP-1, MMP-3, and MMP-13 are interstitial collagenases
typically found in osteoarthritic cartilage and are responsible for the degradation of
collagen fibrils [34]. Both human and equine studies have identified MMP-13 as the
primary collagenase involved in type II collagen degradation in articular cartilage [35, 36].
Aggrecan cleavage is caused by the upregulation of MMPs, as well as aggrecanases, which
belong to the ADAMTS (a disintegrin and MMP with thrombospondin motif) family [33].
Important aggrecanases found in OA cartilage are ADAMTS-4 and ADAMTS-5, with the
latter being the more predominant enzyme involved in degradation [37, 38]. In equine
carpal joints with naturally occurring OA, synovial tissue has shown a significant increase
in the expression of ADAMTS-5 and MMP-13, while the articular cartilage has shown a
significant increase in the expression of ADAMTS-4 and MMP-13 [32].

1.2.3.2 Inflammatory Mediators

Pro-inflammatory cytokines play a significant role in inflammation mediation and
tissue destruction involved in osteoarthritic joints [39-41]. Interleukin-1 (IL-1) and tumor
necrosis factor-α (TNFα) are largely responsible for the mediation of joint disease and have
been shown to control the production of MMPs by chondrocytes and synovial cells [38,
42-44]. These two cytokines, among other inflammatory mediators, have been widely
researched in both human and equine OA [45-49].

5

The first identification of IL-1 in equine OA joints was reported in 1990 [46], and
since then has been extensively evaluated, with the consensus that it is the major cytokine
driving OA development [19]. IL-1 can elicit a cascade resulting in the depletion of
proteoglycans in articular cartilage by increasing the release of MMPs, aggrecanases, and
prostaglandin E2 (PGE2) [8]. The IL-1 system can be broken up into two agonist members,
IL-1α and IL-1β, with the latter being considered the principal mover of the system [38,
50]. The importance of IL-1β in equine OA pathogenesis has been well demonstrated with
the use of interleukin-1 receptor antagonist (IL-1Ra), where it has been demonstrated that
articular cartilage degradation in an experimental equine OA carpus can be inhibited by the
suppression of IL-1 [31, 51].
TNFα was first identified in the horse in 1995 [52], however, its role in OA is not
completely understood today. It has been shown in the equine osteoarthritic carpus that
TNFα is significantly expressed in both the articular cartilage and synovial membrane,
while IL-1β is expressed significantly in the cartilage but not to a large extent in the
synovium [32]. Although TNFα has been identified as the most prominent cytokine present
in the acute stage of OA, IL-1β is pivotal during the early and late stages and concentration
levels remain high during the onset of arthritis [53, 54].
Interleukin 6 (IL-6), which is important in directing the innate immune response to
acquired immunity, has been identified as another important cytokine involved in OA and
is localized in the synovial fluid of arthritic joints [54-59]; however, its exact role is not
completely known. In OA, IL-6 has been shown to upregulate metalloproteinase inhibitors
[60] but also enhance the catabolic effects on proteoglycan metabolism involved with IL1β and TNFα [61-63].
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In addition to pro-inflammatory cytokines, other inflammatory mediators have been
seen as key players in OA pathogenesis, including free radicals and prostaglandins. Free
radicals, such as nitric oxide (NO), may be released following joint tissue injury. NO has
been shown to be produced by osteoarthritic chondrocytes by in vivo experimentation [64]
and increased levels have been identified in OA joints [65, 66]. Free radicals are
responsible for mediating the destructive effects of IL-1 and TNFα in OA cartilage and
excessive amounts cause chondrocyte death and matrix degradation [67].
Prostaglandins are responsible for the decrease in proteoglycans in the cartilage
matrix in response to joint inflammation [68]. Prostaglandin E2 (PGE2) is one of the most
important mediators of pain and inflammation in OA [69] and has been shown to increase
in the synovial fluid of equine osteoarthritic joints in experimental models including
exercise, osteochondral fragmentation, and lipopolysaccharide challenge [70-72]. PGE2 is
responsible for vasodilation, increase in pain perception, proteoglycan depletion in
cartilage, and demineralization of bone. PGE2 can also be used as a useful objective index
for the degree of synovitis in horses [58, 73, 74]. It has been suggested that concentrations
of PGE2 in equine synovial fluid are correlated with to the degree of lameness and joint
pain in naturally occurring OA [58, 75].

1.2.4

Effects of Loading and Exercise

Frequent exercise offers multiple health benefits to the horse and without the
mechanical stimuli from athletic activity articular cartilage can atrophy [76]. Exercise at a
moderate level has been demonstrated in the horse to improve articular cartilage
composition and thickness [77-80]. Moderate exercise also increases the expression of pro7

inflammatory cytokines, which are essential for the long-term adaptive responses to
locomotion and mediating repair processes [81]. Under normal conditions, articular
cartilage is a resilient tissue that has load-bearing characteristics that can withstand high
cyclic loads. After prolonged, repetitive use, however, the adaptive responses can become
deficient in their ability to repair and will eventually fail.
Equine athletes are at a higher risk for the development of joint disease, due to the
degree to which their joints are physically challenged. OA has been deemed one of the
most significant factors of reduced performance in equine athletes [2-4, 20, 21] with some
surveys estimating that up to 60% of lameness is attributable to this progressive joint
disease [82, 83]. Most exercise-related injuries occur as a result of the repeated loading of
a joint and damage that can occur in the bone, joint capsule, or supporting ligaments.
Strenuous, long-term exercise has been shown to cause damage in equine articular cartilage
[84-87] and induce important pro-inflammatory cytokines such as IL-1β, TNFα, and IL-6,
all of which mediate OA processes [88-90]. High-impact mechanical loading causes

chondrocyte apoptosis and therefore leads to alterations in cartilage matrix composition
[91-93]. As such, intense, high impact exercise can outstrip repair processes an lead to a
loss of mechanical competence in articular cartilage where reports have shown a
downregulation in proteoglycans [84, 94-96].

1.2.5

Areas of Occurrence
In equine athletes, joint disease mostly affect high-motion joints in the distal

locations of the limbs. In Thoroughbred racehorses, the most commonly affected joints
involve the carpal, metacarpophalangeal (MCP), and metatarsophalangeal (MTP) joints [2,
8

5, 20, 97, 98]. In western performance horses, of the high motion joints, disease is most
commonly recognized in the medial femorotibial joint in the stifle [99].

1.2.5.1 Fetlock Joint
The MCP and MTP joints, also known as the fetlock joints, are composed of the
first phalanx, a pair of proximal sesamoid bones, and the distal aspect of the third
metacarpus or metatarsus [8]. Clinical studies have shown that the MCP joint is the most
commonly affected joint in racing horses that experience a higher incidence of condylar
fractures than other equine performance disciplines [86]. OA in the fetlock can be caused
by fragmentation, fracture, or luxation. These joints are predisposed to injury due to their
extreme range of motion, high impact forces and minimal soft tissue covering; it has been
estimated that they undergo five to seven times their body weight in stress, with ground
reaction and muscle forces taken into account [8].

1.2.5.2 Carpal Joint

The equine carpus involves three main articulations, the antebrachiocarpal
(radiocarpal), middle carpal (intercarpal), and carpometacarpal joints [8]. Most cartilage
lesions are found in the middle carpal joint [100, 101], with one study in Standardbred
pacers reporting that 30% of horses experienced middle carpal joint lameness in their first
12 to 18 months of training [102]. The dorsal aspect of the carpal joints are more
susceptible to injury because they experience intermittent high-loading conditions, while
the palmar sites experience lower and more constant weight-bearing [103].
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1.3

Intra-Articular Corticosteroids
The first report of corticosteroid use in musculoskeletal conditions of the horse was

published in 1955 [104] and since then, they have become the most popular treatment to
reduce lameness and joint effusion associated with OA [97, 105, 106]. Corticosteroids are
a class of steroid hormones produced by the adrenal cortex and they can be further
categorized into glucocorticoids and mineralocorticoids [107]. Pharmacotherapeutic use of
glucocorticoids for joint disease utilize their ability to decrease catabolic and proinflammatory factors in articular cartilage and synovial membrane [32]. There are currently
four FDA-approved formulations for intra-articular glucocorticoid administration in the
horse: triamcinolone acetonide, betamethasone acetate, betamethasone phosphate, and
methylprednisolone acetate. Race and competition horses are often treated with these
corticosteroids to combat the excessive inflammation that often follows the high-intensity
nature of their exercise regimes and performance. It has been reported for Thoroughbreds
that 21% of racehorses have received at least one IA corticosteroid injection, and of those,
50% have been injected on multiple occasions [97]. Triamcinolone acetonide and a mixture
of betamethasone esters are the two most commonly utilized corticosteroids for both high
and low motion joints by equine veterinarians [97] and methylprednisolone acetate usage
has significantly decreased over the past ten years due to the prolonged half-life and
deleterious effects on the joint [106].

1.3.1

Chemistry

10

Therapeutic glucocorticoids are structurally similar to cortisol, consisting of a 21carbon and 4-ring steroid skeleton [108]. The pharmacological differences between
individual synthetic glucocorticoids can be attributed to alterations in this chemical
structure. These adaptations can cause differences in the potency of anti-inflammatory
effects, relative affinity for receptors, and degree of protein binding [109]. The biological
potency and activity of IA corticosteroids are dependent on many factors such as the total
dose administered, treatment frequency, duration of action, conversion rate to biologically
active metabolites, and suspension crystal size, however, synthetic glucocorticoids are
considered to be much more potent than endogenous corticosteroids [110].

1.3.2

Mechanism of Action

Glucocorticoids are potent anti-inflammatory and immunosuppressive agents that
have a complex mechanism of action. They are small lipophilic molecules that can readily
cross cell membranes by diffusion to enter the cytoplasm of cells [111]. Once inside the
cell, they bind to a cytosolic glucocorticoid receptor (cGCR) where they then move to the
nucleus, resulting in two main outcomes: transrepression and transactivation [109]. During
transrepression, the activated complex will bind to transcription factors, subsequently
suppressing their function and causing the down-regulation of gene expression for proinflammatory cytokines, chemokines, inflammatory enzymes, prostaglandins, and
adhesion molecules. Important pro-inflammatory cytokines suppressed by glucocorticoids
include IL-1, IL-2, IL-3, IL-6, TNFα, and IFN-γ. In transactivation, the complex will bind
to gene promoters and activate transcription of anti-inflammatory genes such as IL-10, κB
kinase inhibitor, annexin-1, and lipocortin-1.
11

Glucocorticoids are well known for their inhibitory effects on cellular and humoral
inflammatory processes reducing pain and inflammation. In addition to their
responsibilities of reduction in capillary dilatation, margination, migration, and
inflammatory cell accumulation [112-114], they also inhibit the synthesis and release of
mediators involved in the arachidonic acid pathway [112]. The glucocorticoid-induction of
lipocortin inhibits phospholipase A2, the enzyme responsible for inducing the arachidonic
acid cascade. This inhibition of phospholipase A2 will impair both the cyclooxygenase and
lipoxygenase pathways and subsequent production of prostaglandins, thromboxanes, and
leukotrienes, thus leading to the reduction of pain and inflammation.
Aside from pain relief and reduction of inflammatory mediators, IA corticosteroid
use has also been reported to have chondroprotective effects in increasing synovial fluid
[115, 116] and endogenous hyaluronate (HA) release [117].
As mentioned previously, therapeutic glucocorticoids are structurally similar to
cortisol. Cortisol is considered an anti-inflammatory steroid hormone that regulates
inflammation and immune function [118, 119]. Anti-inflammatory effects occur from the
inhibition of nuclear translocations and several pro-inflammatory transcription factors,
which then suppresses synthesis of inflammatory mediators such as cytokines and
prostaglandins [120]. This glucocorticoid is produced by the adrenal glands and is
controlled by adrenocorticotropic hormone (ACTH), a hormone made by the anterior
pituitary gland, and corticosteroids are known to decrease secretion of ACTH through the
suppression of the hypothalamic-pituitary-adrenal axis [118-121]. During exercise, cortisol
is important for the maintenance of homeostasis and the magnitude of the stress response
is affected by the intensity and duration of exercise [122, 123].

12

1.3.3

Triamcinolone Acetonide
Triamcinolone acetonide (TA) is the most frequently used IA corticosteroid in

equine practice, making up 65% of local corticosteroid injections chosen by equine
veterinarians [97]. The total dosage of TA administered typically ranges from 5 to 40 mg
with a median of 10 mg [97]. A 2009 survey of veterinarians of various disciplines reported
that 77% of clinicians used TA in high-motion joints, such as carpal and fetlock joints, and
that 34% used the drug in low-motion joints [105]. Ten years later, it was reported that TA
was used by 80% of veterinarians to treat high motion joints, suggesting there has not been
a significant difference in TA use in the past decade, further emphasizing the reliance on
the drug [106].

1.3.3.1 Pharmacokinetics

Triamcinolone acetonide is a potent synthetic glucocorticoid that is considered to
have a medium duration of action. The plasma pharmacokinetics of TA following 9 mg of
IA administration to exercised Thoroughbreds has been reported to have an average halflife of 19 hours [124]. That study indicated that TA in synovial fluid was detectable for up
to 35 days and in the blood for 7 days. Studies using a lower dose have reported shorter
half-lives of IA TA [125, 126].

1.3.3.2 Efficacy

13

Triamcinolone acetonide is the preferred corticosteroid for the treatment of joint
disorders because of its chondroprotective effects and highly effective control of
inflammation. Multiple in vitro and in vivo studies have demonstrated these effects in the
horse. A study using equine articular cartilage explants has suggested that TA protected
chondrocytes from the pro-inflammatory effects of lipopolysaccharide (LPS), based on
similar GAG content to controls [127]. LPS has also been used in an in vivo study where
MCP joint synovitis was experimentally induced to observe the analgesic and antiinflammatory actions of TA [128]. The medication was found to reduce lameness, edema,
and synovial fluid protein concentrations.
The effects of IA TA have also been examined in exercised equine athletes with
carpal osteochondral fragmentation using a dosage of 12 mg in both joints [73]. It was
found that horses treated with TA showed a decrease in lameness and synovial fluid total
protein, as well as an increase in hyaluronic acid concentrations in synovial fluid. The
favorable effects of TA can also be attributed to the fact that the synovial membrane had
significantly less inflammatory cell infiltration, as well as a decrease in subintimal
hyperplasia and fibrosis. It is important to note that 12 mg is considered a higher dose for
TA and that the relationship of corticosteroid dose to potential effects is important as
chondrocyte studies in both horses and humans have shown dose-dependent chondrotoxic
effects [129-131].
The disease-modifying activities of TA have also been evaluated in equine cartilage
explants using serine protease-activated protein C (APC), a protein derived from human
chondrocytes located in areas of pathological cartilage fibrillation [132]. In the study, APC
synergized with IL-1 and TNFα, leading to significant degradation of collagen in cartilage
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explants. The drug was shown to cause a significant decrease in MMP-1, MMP-3, and
MMP-13 mRNA. TA has also been reported to inhibit the upregulation of MMP-13 and
COX-2 in recombinant equine IL-1β stimulated articular cartilage explants [133].

1.3.3.3 Combined Use with Hyaluronan

In clinical practice, TA is frequently combined with sodium hyaluronate (HA), with
one study reporting that 61% of veterinarians use HA when using TA intra-articularly [97].
This glycosaminoglycan is responsible for the formation of proteoglycan aggregates, gives
synovial fluid its viscoelasticity, and is the principal lubricant of synovial soft tissues [112].
Its pharmacologic effects are believed to provide additional benefits in clinical
improvement and chondroprotection with the use of TA [8, 112, 134]. Joint injection with
HA alone has been shown to display direct analgesic effects without causing harm to the
articular cartilage or the synovial membrane [135] and it is responsible for reducing
friction, synovial prostaglandin E2 release, cartilage fibrillation, and IL-1 induced
proteoglycan loss [136-138]. However, because HA has a short IA half-life [139], which
is even further reduced during synovitis [140], HA is believed to be a better choice in the
treatment of early joint lesions than in established disease [112].
Even though the combined use of TA and HA is popular in horses, there are limited,
indirect, and conflicting studies on the metabolic effects of this combination on joint
metabolism. It has been reported in horses and humans that the combination has either
minimal [141-143] or no overall benefit [144, 145]. It has also been reported that the
combined use of high molecular weight HA with TA in lame horses had a lower success
rate in improving lameness compared to horses treated with TA solely [146].
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1.3.4

Betamethasone
Betamethasone is typically used as a mixture of two betamethasone esters: the

slow-release betamethasone acetate and the water-soluble betamethasone sodium
phosphate. The typical recommended dosage of the drug is 9 mg for the treatment of OA
[147]. Their frequency of use in the treatment of high motion joints has been reported at
31% of Thoroughbred racehorses, making it second to TA [97]. A recent study reported
that the frequency of use has slightly increased within the past 10 years and that 33% of
veterinarians chose betamethasone for high motion joints and 17.3% use the drug for lowmotion joints as of 2019 [106].

1.3.4.1 Pharmacokinetics

Betamethasone is considered short-acting in horses and the medication has been
shown to reach peak concentration at a quicker rate and have a shorter half-life compared
to TA [124, 131, 148]. The rapid absorption rate can be attributed to the high aqueous
solubility of the phosphate ester [108]. Maximum drug concentrations in plasma have been
seen at 2 hours following the IA injection of 9 mg of a betamethasone sodium phosphate
and betamethasone acetate suspension [148]. The plasma elimination half-life was reported
at approximately 7.5 hours and the half-life in synovial fluid was reported at 194 hours.

1.3.4.2 Efficacy
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There are limited published studies on the efficacy and anti-arthritic effects of
betamethasone IA injections. A commonly cited study explored the effects of
betamethasone and exercise on equine carpal joints with experimentally-induced
osteochondral fragments and found beneficial effects [147]. Joints were injected with 3.9
mg betamethasone sodium phosphate and 12 mg betamethasone acetate and horses were
then exercised on a high-speed treadmill. Findings suggest that there were no significant
detrimental changes to cartilage in exercised or unexercised horses and that the exercised
horses had comparable GAG concentrations compared to saline-treated joints.

1.3.5

Deleterious Effects of Corticosteroids
The use of corticosteroids is not without controversy. The reported adverse effects

include progressive cartilage degeneration, calcium deposit formation of the surface of
hyaline cartilage, cartilage thinning, as well as a decrease in cartilage elasticity, GAG
content, synovial fluid viscosity, and HA [149]. There are also some case reports that link
corticosteroids to laminitis in susceptible horses [150, 151], however, there are numerous
studies in scientific literature in which horses were administered large doses of IA
corticosteroids over a prolonged period of time and did not develop laminitis.
Although TA is the most commonly chosen corticosteroid for IA injections, there
are several accounts of deleterious effects; however, most of these reports utilize a higher
dosage typically used in practice. One study concluded that methylprednisolone and TA
did not counteract the negative effects of IL-1 and suppressed cartilage metabolism when
using IL-1α conditioned equine cartilage explants [152]. It is also important to note that in
this study, TA appeared to be as equally harmful as methylprednisolone on cartilage
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metabolism. It has also been reported that repeated injections of TA on normal joints
promoted loss of resident and newly synthesized aggrecan and collagen molecules [153].
Although the observed findings suggest that long-term IA treatment of TA may lead to
deleterious effects on cartilage metabolism, the author stated that further research is needed
to confirm the claim, as the drug was administered to healthy joints unrepresentative of
equine OA. TA has also displayed a potentially detrimental effect in increased synovial
PGE2 levels, although these effects were short-lived [154]. It was also suggested that the
drug was continuing to display anti-inflammatory effects up to 14 days after treatment,
which is longer than originally reported.
There have been multiple reports of the detrimental effects on equine articular
cartilage based on proteoglycan depletion and/or suppression of GAG synthesis, although
most have been with methylprednisolone acetate [154-164]. Proteoglycan synthesis in
normal equine cartilage explants has been shown to be severely depressed by clinical doses
of both methylprednisolone acetate and TA [165, 166]. In vitro IL-1 stimulated explants
have also shown that methylprednisolone acetate and TA increase GAG release [165, 167].
The anti-inflammatory properties of corticosteroids can be beneficial for the return
of normal homeostasis within the joint, however, there is concern that the effects of the
drugs may ameliorate clinical signs before pathology has resolved. This can lead to the
masking of a musculoskeletal injury, which can then become exacerbated during exercise
and performance. There is also long-standing controversy that the overuse of a painmasked joint accelerates the deterioration of cartilage, which is based on the negative
effects of corticosteroids on chondrocyte metabolism [112, 131] and downregulation of
collagen gene expression [168]. Underlying musculoskeletal injuries put the safety of the
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horse at risk, as most catastrophic injuries occur in areas with pre-existing pathology, which
has been well established [97, 169-173].

1.3.6

Rules and Regulations
To avoid the potentially detrimental effects of corticosteroids and maintain the

integrity of the sport, race and sport horse organizations have established regulations to
control their use. The Association of Racing Commissioners International (RCI) has
established ‘model rules’ for anti-inflammatory drug use that are provided as a standard
for regulation of Thoroughbred, Quarter Horse, Standardbred, and Arabian racing. As of
2019, the association allows the use of IA corticosteroids no less than 14 days prior to race
day for flat and jumps racing [174]. No detection of the drugs is allowed on race day and
there is also a prohibition on the stacking of corticosteroids.
The United States Equestrian Federation (USEF) is responsible for the drug
regulation of 18 national and international competitive equestrian disciplines, including the
Olympic and Paralympic disciplines [175]. As of 2022, the USEF does not allow the use
of IA corticosteroids seven days prior to competition. The current withdrawal regulations
for these organizations are established for the safety of the horse and the integrity of the
sport, but the lack of information regarding the effect of these drugs on inflammatory gene
expression challenges the intention of the rules.

1.4

Intra-Articular Lipopolysaccharide Model
Experimental models that mimic the pathogenesis of joint disease are widely utilized

in research to better understand OA and the effectiveness of treatment options. Different
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types of experimental models of OA have been described in the horse including the IA
injection of chemicals such as filipin [23, 176], sodium monoiodoacetate [177, 178],
amphotericin B [179, 180], autogenous articular particles [181], and iatrogenic
hemarthrosis [182]. The carpal osteochondral fragment-exercise model has also been a
popular way to mimic joint disease [28, 73, 147, 158, 183]. Although these models have
been useful to explore joint pathology of OA, they only focus on cartilage destruction
instead of synovial membrane inflammation on articular cartilage metabolism. The use of
lipopolysaccharide (LPS) in an inflammation model has become increasingly popular to
induce a transient, localized source of inflammation and monitor a systemic immune
response [184-190] and it has also been widely used to study the anti-inflammatory
potential of therapeutics [191-195].

1.4.1

Lipopolysaccharide

Lipopolysaccharide (LPS), also known as endotoxin, is the major component of the
outer membrane of gram-negative bacteria and is released from bacterial cells during cell
death or reproduction. LPS is a large glycolipid composed of the O-antigen, a
polysaccharide core, and a lipid A molecule [196]. Lipid A is the moiety released into the
blood that is responsible for eliciting systemic inflammatory and immune reactions in the
body. LPS is a specific activator of innate immunity and it can stimulate monocytes,
macrophages, and neutrophils to produce inflammatory mediators. Once LPS has breached
the defensive barriers, the endotoxin will first interact with LPS-binding protein (LBP),
which will facilitate binding to CD14. This complex will then recruit and activate TLR-4
present on mononuclear phagocytes, neutrophils, dendritic cells, and endothelial cells.
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MD-2, an accessory component is then recruited for intracellular signaling. Ligation of
TLR-4 will initiate downstream pathways and stimulate NF-κB to produce inflammatory
cytokines, TNF-α, IL-1β, IL-6, IL-8, IL-12, IL-18, as well as the chemokine IL-8 [196].
This production of inflammatory mediators activates a ‘cytokine storm,’ which causes a
flood of inflammatory, procoagulant, and vasoactive facilitators.

1.4.2

Systemic Response
A ‘proper’ inflammation model will elicit an immune response, closely resemble

joint disease, have no long-term deleterious effects, and can be repeated to produce the
same result. Acute synovitis inflammation models utilizing LPS typically stimulate an
upregulation in inflammatory mediators and enzymes, as well as increase lameness, vital
signs [59, 195], white blood cell counts [59, 195], and joint swelling and heat [72, 197]. In
joints, equine chondrocytes have been shown to be more responsive to LPS when compared
to dogs and other mammals with a susceptibility that is 10 times greater compared to other
species [198]. Because of this sensitivity, response to LPS is greatly variable and can be
highly sensitive to the age of the horse, location of injection, frequency of injections, and
the dosage and serotype of the endotoxin.

1.4.2.1 Inflammatory Mediators and Enzymes
Intra-articular administration of LPS has been shown to stimulate a release of
inflammatory cytokines, mediators, and enzymes implicated in arthritic disease. Increases
in IL-1β, IL-6, and TNFα are commonly observed in equine LPS models and have been
seen to be released by both the articular cartilage and synovial membrane [56, 59, 199].
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An upregulation of MMP activity has also been identified in these models, with MMP-1, 8, and -13 collagenases shown to be increased in synovial fluid assays [71, 190, 200, 201].
Additionally, LPS increases mRNA expression of MMP-1 and ADAMTS-4, and
ADAMTS -5 in both articular cartilage and synovium [200]. Serum amyloid A (SAA),
which can lead to induction of increased MMP activity [202-204], has also been identified
to have an important pathophysiological role in equine arthritis using LPS-induced models
[205-207].
It has been demonstrated in the horse that LPS causes an acute and short-lived
upregulation of PGE2 synthesis in IA models [56, 71, 72, 200, 201, 208]. The increase in
PGE2 is believed to contribute to pain-associated lameness as well as changes in cartilage
turnover markers, as the eicosanoid is known to have a major role in cartilage degradation
in arthritic joints [209, 210]. PGE2 response has also been seen to vary with age where
older horses have produced significantly greater concentrations compared to younger
horses [208, 211].
IA injection of LPS has also been shown to influence the metabolism of articular
cartilage. For example, collagen type II turnover has been seen to increase following IA
LPS injection in mature horses [71]. The response for collagen type II markers is typically
delayed and persists longer compared to other biomarkers with concentrations of catabolic
collagenase cleavage neopeptide (C2C) and anabolic carboxypeptide (CPII) both being
elevated over seven days. C2C is associated with collagen II cleavage [71] and CPII is
typically associated with models of equine OA [31]; their increase is interpreted as a
reparative response to the collagen network. The study also found that synovial C2C and
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CPII were affected by the age of the horse with concentrations of both being lower in
yearlings and 2-3 year-olds compared to mature horses [208].
LPS in synovitis models has also shown an acute, transient response of
proteoglycans in synovial fluid [190, 212]. The endotoxin has been shown to stimulate a
significant GAG release in synovial fluid [71, 201], as well as the CS826 epitope, which
has been thought to reflect the turnover of aggrecan molecules [213]. An increase in
synovial substance P and bradykinin have also been reported [71]. Substance P is
associated with cartilage degradation in OA [210], but the effects of bradykinin on articular
cartilage remain unknown.

1.4.2.2 mRNA Expression of Inflammatory Mediators
Many studies have focused on parameters associated with the localized
inflammatory response and synovitis, however, until recently, there had been a lack of
information regarding systemic mRNA response to LPS. In 2018, a study evaluated
systemic cytokine gene expression in response to 0.25 ng and 0.50 ng of LPS in Quarter
Horse yearlings, but only a mild immune response was elicited [214]. The limited changes
in systemic inflammatory gene expression may have been a result of an insufficient dose
of LPS or repeated arthrocentesis where endotoxin could have been progressively removed.
To complement this work, a 2020 study utilized an LPS dosage larger than the
previous experiment to elicit a significant immune response and evaluate gene expression
[206]. The goal of the study was to refine an LPS experimental model to induce acute
synovitis to explore mRNA expression and to develop a model for future use that could
investigate the effects of anti-inflammatory drugs on inflammatory gene expression. With
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an LPS dose of 3 μg, serum amyloid A (SAA) concentrations significantly increased and
multiple genes exhibited a significantly different expression profile, including CD14,
TLR4, MMP-1, MMP-9, IL-1β, IL1RN, IL-10, ALOX5AP, IL-8, TNFα, CCL8, IGF1, and
PTGS2. This study also found that there was a more robust response in horses where the
radiocarpal joint was injected compared to the metacarpophalangeal joint, as well as a
more robust response in younger versus older horses. This study demonstrated that the
measurement of mRNA expression provides sensitive and rapid information regarding the
inflammatory response to this type of LPS model. This study also attempted to quantify
circulating cytokine concentrations in serum, however, the authors were unsuccessful using
commercially-available assays.

1.4.3

Lameness
When assessing lameness, most studies rely on the American Association of Equine

Practitioners (AAEP) lameness scale [215] where horses are trotted in a straight line and
then assigned a score from 0 (sound) to 5 (non-weight bearing) [71, 72, 146, 197, 214]. In
some research, the experimental setup does not allow for the horses to be trotted and/or
lameness is too severe for the AAEP scale, therefore some studies have created their own
scales [206, 207].
There is wide variability in the timing of lameness reported post-LPS infiltration.
Most studies have reported peak lameness to occur 6-8 hours after induction of LPS [128,
190, 191, 193, 212, 216-219], while others have reported the peak to be at 4 hours postinjection [200, 220-224]. While lameness can be significant during these experiments, it
typically resolves within 48 hours of injection [214, 224, 225]. Although the transient and
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self-limiting nature of the LPS model is considered a benefit, it is also frequently cited as
the main limitation as it is not completely representative of naturally occurring OA. In
horses with joint disease, recurring and/or constant inflammation plays a critical role in
both the development and progression of joint disease and to replicate this, some studies
utilize the repeated injections of LPS with 2- to 3-week wash-out periods [154, 206, 207].

1.4.4

Dosage

The first study to utilize IA administration of LPS aimed to study infectious arthritis
in the middle carpal joint of ponies utilizing a dosage of 25 to 45 μg [226]. All ponies were
reported to be lame within 2 hours post-injection of LPS and all exhibited signs of systemic
endotoxemia including neutrophilic leukocytosis, fever, depression, and an increase in
heart and respiratory rates. Clinical signs subsided within 36 hours after injection. Since
the first LPS synovitis study, a large variety of dosages of LPS have been used for
experimental joint inflammation, ranging from 0.125 ng to 5000 ng [197]. The lower doses
have been reported to produce mild lameness whereas the higher doses have been seen to
cause significant, non-weight bearing lameness.
A dose of 0.5 ng of LPS has been frequently utilized in IA injection studies and has
shown increased synovial fluid inflammatory biomarker, MMP activity, and markers for
cartilage turnover [71, 78, 200, 221, 227, 228]. Sub-nano doses are commonly used in
studies of the repeated arthrocentesis of LPS to prolong inflammation [72, 212, 214],
although higher doses are also seen in these types of models to elicit a more robust response
[128, 206]. Some researchers also decide to use a lower dosage when injecting bilateral
joints in both single injection and repeated injection study designs [154, 195].
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Larger dosages have been seen to produce significant lameness and systemic
endotoxemia symptoms in horses [56, 197, 206]. A recent study aimed to explore various
LPS doses that would induce systemic inflammatory mRNA expression but cause less
severe lameness compared to other studies [207]. LPS doses of 1, 10, 100, 1,000 ng were
injected into the radiocarpal joint and horses were assessed utilizing a novel lameness scale.
It was found that LPS dosages of 10 ng or higher elicited non-weight bearing lameness and
the 1 ng dose did not cause lameness or a significant circulating mRNA change. Findings
suggested that select mRNA expression exhibited dose-dependent changes, however,
lower LPS dosages were not able to reduce the severity of lameness but maintained a robust
mRNA response.

1.4.5

LPS Serotype
Discrepancies seen in both dose response and timing of lameness have been thought

to be correlated with the origin of the LPS used. LPS purified from E. coli is the most
frequently used LPS in inflammatory models and multiple strains can be used, including
O55:B5, O127:B8, and O111:B4. LPS derived from E. coli O55:B5 is utilized by the
majority of studies [56, 72, 197, 214, 226], but more work is currently being done with E.
coli O111:B4 [206, 207].
It has been demonstrated in mice that there are significant differences between E.
coli O55:B5 and O111:B4 serotypes on body temperature [229] and myometrial activation
of inflammatory transcription factors [230]. These inconsistencies are believed to be due
to the subtle changes in sugar composition of the O-antigen in LPS, thus changing the
interaction with LPS and TLR4 receptor complex and differentially activating functional
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pathways [231]. It has also been reported that biological activity can vary even within the
same strain and mass of LPS where strain disparity has been shown in different serotypes
of LPS derived from Porphyromonas gingivalis [232].

1.4.6

Endotoxin Tolerance

A common problem in repeated measure design studies with the use of LPS is
endotoxin tolerance, which is a transient desensitization to LPS. Endotoxin tolerance is
associated with a diminished pro-inflammatory and clinical response to endotoxin [233],
which could affect study results when repeated LPS exposure is used. The main
characteristics of endotoxin tolerance are a diminished clinical response and the
downregulation of inflammatory mediators such as TNF-α and IL-1β [233, 234].
Conversely, various studies have shown endotoxin tolerance with an increase in IL-1 [235,
236], making the exact mechanisms unclear. These discrepancies are likely associated with
the purity, type, and dose of LPS.
Another main characteristic of endotoxin tolerance is the upregulation of antiinflammatory cytokines such as IL-10 and TGF-β [233]. This effect may be due to the
inhibition of pro-inflammatory TLRs and IL-1 receptor signals, leading to negative
regulation of innate immune responses. In horses, the duration of endotoxin tolerance in
vivo with a 30 ng/kg LPS intravenous infusion was seen to last for 7 days and subside by
14-21 days [237]. These authors concluded that a minimum of a 3 week washout period
between experiments is suggested when using similar dosages in repeated measures
designs.
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1.5

Overall Objectives and Hypothesis
Intra-articular corticosteroids are frequently used in equine athletes to combat the

sequelae of joint disease that results from the high-intensity nature of training and
performance. Triamcinolone acetonide and betamethasone are commonly utilized by
equine practitioners to control pain and inflammation as well as to interrupt the onset of
permanent

osteoarthritic

changes.

The

anti-inflammatory

properties

of

these

corticosteroids typically ameliorate lameness that occurs with joint disease, however, there
is concern that the long-lasting effects of the drugs may improve clinical signs before
pathology has resolved [238]. This can potentially lead to the masking of musculoskeletal
injuries, which may then become exacerbated during exercise and performance [97]. There
is also long-standing controversy that the overuse of a painless joint accelerates the
deterioration of cartilage [168].
Importantly, in the context of Thoroughbred racing, underlying musculoskeletal
injuries put the safety of the horse and rider at risk as most catastrophic injuries occur when
underlying pathology is present [97, 169-173]. As such, regulatory and athletic discipline
organizations have adopted withdrawal guidelines to avoid these deleterious effects, as
well as to protect the safety of the horse and the integrity of the sport.
Recent work by our group and others have examined the effects of exercise and
injury on equine inflammatory gene expression [70, 239-246], however, further research is
needed to investigate how anti-inflammatory drugs affect this expression. The goal of this
study is to utilize an acute synovitis inflammation model [206] to determine the effect of
intra-articular corticosteroids on pro- and anti-inflammatory markers, thus providing
additional information on these commonly used therapeutic medications in equine athletes.
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We hypothesized that horses treated with intra-articular corticosteroids (triamcinolone
acetonide and betamethasone) will display a difference in systemic mRNA expression 14
days after administration when compared to a control.
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CHAPTER 2. RESIDUAL EFFECTS OF INTRA-ARTICULAR BETAMETHASONE
AND TRIAMCINOLONE ACETONIDE IN AN EQUINE ACUTE SYNOVITIS
MODEL
2.1
2.1.1

Materials and Methods
Horses
A group of five, 2-year-old horses (1 gelding, 4 fillies) of mixed breeds were

utilized for this study. All horses were deemed healthy by baseline bloodwork and physical
assessment prior to the start of the study. Additionally, horses used had no history of prior
corticosteroid administration.
The day prior to injection, horses were placed into their individual stalls with hay
and water ad libitum. On the morning of injections, horses received examinations of vital
signs and soundness. At all sample collection time points (below), horses were circled with
the injected leg to the inside and, using a previously reported lameness scale [207], a grade
of 0 to 5 was recorded (0 = sound, 1 = intermittent lameness, 2 = consistent mild lameness,
3 = consistent significant lameness, 4 = minimally weight-bearing, 5 = non-weight
bearing). Due to the severity of lameness and inability to initially (<24 hours) assess horses
outside of their stall, this scale was chosen over the commonly utilized American
Association of Equine Practitioner scale [247]. Following the 12-hour post-injection
examination, horses were turned out as a group. The University of Kentucky’s IACUC
approved all procedures.

2.1.2

LPS Preparation
Frozen aliquots of lipopolysaccharide (LPS) (5 mg/mL) derived from E. coli

O111:B4 (Millipore Sigma-L2630) in sterile phosphate-buffered saline (PBS) were thawed

approximately 15 minutes before injection and diluted with saline to a concentration of 1
μg/mL LPS. Immediately following dilution, 1 mL of the solution was injected into the
flexed radiocarpal joint (below). A new dilution was made for each horse and, while the
same lot of LPS was used throughout the study, a new LPS stock was thawed for each
treatment week. LPS dosage and joint location were determined based on previous work
[206, 207].

2.1.3

Intra-Articular Injections
For all joint injections, horses were sedated with xylazine at ~0.4 mg/kg IV and the

dorsal surface of the radiocarpal joint aseptically prepared. All radiocarpal joint injections
(LPS, corticosteroid, or saline) were separated by 14 days, as depicted in Figure 2.1.
Initially, an LPS injection (LPS #1) was carried out, followed two weeks later by a single,
9mg IA dose of either betamethasonea or triamcinolone acetonideb, chosen randomly, into
the opposite leg (CS #1). Following a 14 day waiting period, horses were injected with
LPS into the same joint as CS #1. Treatment with the corticosteroid was then crossed over
and the injections repeated (CS #2). Following a final, LPS-only injection (LPS #2), horses
were

injected

with

1

mL

of

saline
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for

use

as

a

negative

control.

Figure 2.1 Design and timeline for the experiment. Each injection was separated by 14 days
and joints were alternated. CS denotes the corticosteroid used for injection.

2.1.4

Sample Collection and Processing
Blood was collected via jugular venipuncture prior to any IA injection, as well as

2, 4, 6, 9, 12, 24, 48, 72, and 144 hours post-injection. Serum was collected at all time
points following centrifugation (800g x 10 min) and then frozen at -20 °C. Sera from all
pre-injection samples were tested for quantification of both corticosteroids using liquid
chromatography tandem mass spectrometry at the University of Kentucky’s Equine
Analytical Chemistry Laboratory following the end of the study. Additionally, serum
samples from all time points (as well as 96 and 120 hours post-injection) were analyzed
for cortisol concentrations by Cornell University’s Endocrinology Laboratory. EDTA
tubes were used for complete cell blood count (CBC) and serum amyloid A (SAA). CBCs
were performed using a Vetscan HM5 Hematology Analyzer per the manufacturer’s

32

instructions while SAA was quantified using a commercially available kit and
corresponding reader (StableLab). Blood in lithium heparin tubes was collected preinjection as well as 12, 24, 48, 72, and 144 hours and were utilized for chemistry panels
using a Vetscan VS2 Chemistry Analyzer.
Tempus tubes were also collected and stored per the manufacturer’s
recommendations. Total RNA was isolated and samples analyzed via RT-qPCR using
methods previously described [246]. Relative quantities (RQs) of mRNA expression were
calculated utilizing β-glucuronidase (β-Gus) as the endogenous control for all samples
[206, 207, 248, 249] and the delta-delta CT method [250] using the pre-injection samples
from each horse serving as its own calibrator [206, 207]. Samples were assayed in duplicate
for the following genes using commercially available primers and probes (ThermoFisher
Scientific):

β-GUS

(Ec03470630_m1),

ALOX5AP

(Ec06974239_m1)

CCL8

(Ec03469486_s1),

CD14

(Ec03468689_m1),

IL-1β

(Ec04260298_s1),

IL1RN

(Ec03468678_m1),

IL-8

(Ec03468860_m1),

IL-10

(Ec03470747_m1),
(Ec04260516_gH),
(Ec03468814_m1),
(Ec03468647_m1),

BMP-2
IGF-1
IL-6
MMP1

(Ec03468020_m1), MMP2 (Ec03469995_m1), MMP9 (Ec03469193_m1), Osteoprotegrin
(Ec07007303_m1),

PTGS1 (Ec03469511_m1), PTGS2 (Ec03467558_m1), RANKL

(Ec06625532_m1),

SAA1

(Ec04321145_s1),

TGFβ

(Ec03468030_m1),

TLR-4

(Ec03468994_m1), TNF-α (Ec03467871_m1), TNFSF13B (Ec04320166_m1), and
VEGFA (Ec03467879_m1). The proteins for which these genes encode play an important
role in inflammation, bone repair, bone remodeling, tissue repair, and response to injury.

2.2

Data Analysis
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SigmaPlot 14.5 (Systat Software, Inc.) was used for all statistical analysis and
relative quantity (RQ) data were logarithmically transformed to achieve normality, when
possible. Two-way repeated measures analysis of variance (ANOVA) was used to examine
mRNA expression, CBC differences, chemistry panel analytes, SAA concentrations,
lameness severity, and serum cortisol concentrations by time point and treatment. Results
were considered significant if p<0.05. Persistent corticosteroid treatment effects in spite
of LPS challenge were considered to be present if there was no significant difference
between the corticosteroid treatment and saline control, but there was a significant
difference between the saline control and the LPS-only treatments at the corresponding
time point. Corticosteroid-only treatments were compared to the control and each other to
evaluate gene expression and cortisol changes in steroid treatment after initial
administration.

2.3
2.3.1

Results
LPS-Challenged Treatments
Triamcinolone treatment followed by subsequent LPS challenge demonstrated a

significant treatment effect on IL-6 expression at 12 and 24 hours post-LPS injection
(Figure 2.2) and a significant treatment effect on PTGS1 expression at 9 and 12 hours postinjection (Figure 2.3). Betamethasone only demonstrated a significant treatment effect on
IL-6 at 12 and 24 hours (Figure 2.2). Gene expression for both cytokines increased in LPSonly treatments (LPS #1 and LPS#2) when compared to the saline control.
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Figure 2.2 IL-6 expression at designated time points comparing the saline control to LPS
challenged steroid treatments (“Betamethasone + LPS” and “Triamcinolone + LPS”) and
LPS only treatments (“LPS #1” and “LPS #2”). Error bars represent standard deviation. *
denotes a significant treatment effect. As the calibrator, the pre-injection time-point has
been excluded due to its 0 value.

Figure 2.3 PTGS1 expression at designated time points comparing the saline control to LPS
challenged steroid treatments (“Betamethasone + LPS” and “Triamcinolone + LPS”) and
LPS only treatments (“LPS #1” and “LPS #2”). Error bars represent standard deviation. *
denotes a significant treatment effect. As the calibrator, the pre-injection time-point has
been excluded due to its 0 value.

35

Utilizing the adapted lameness scale detailed above, horses challenged with LPS
14 days after triamcinolone treatment experienced a decrease in lameness severity
compared to other treatments (Figure 2.4) and a significant treatment effect at the 9 and 12
hours post-injection. Further, triamcinolone treatment resulted in horses being completely
sound 12 hours post-IA injection, a finding not observed with the LPS-only or
betamethasone treated joints. No treatment effects of betamethasone on lameness were
noted. In LPS-only treatments (LPS #1 and LPS#2), lameness increased when compares to
the saline control.

Figure 2.4 Lameness grades at designated time points comparing the saline control to LPS
challenged steroid treatments (“Betamethasone + LPS” and “Triamcinolone + LPS”) and
LPS only treatments (“LPS #1” and “LPS #2”). Lameness severity was graded on a scale
between 0 and 5 when horses were circled at a walk (0 = sound, 1 = intermittent lameness,
2 = consistent mild lameness, 3 = consistent significant lameness, 4 = minimally weight
bearing, 5 = non-weight bearing). Error bars represent standard deviation. * denotes a
significant treatment effect. Pre-injection time-point has been excluded due to its 0 value.

With respect to other indicators of inflammation, all pre-injection samples and all
control samples displayed undetectable levels of SAA. While corticosteroid treatment did
not delay the time course for increases in SAA following LPS injection (Figure 2.5), there
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was a triamcinolone treatment effect at 24, 48, and 72 hours. Further, residual treatment
effects of triamcinolone were noted in serum cortisol concentrations at 2, 6, and 9 hours
post-LPS injection (Figure 2.8). SAA concentrations increased in LPS-only treatments
(LPS #1 and LPS#2) when compared to the saline control.

Figure 2.5 Serum amyloid A (SAA) concentrations at designated time points comparing
the saline control to LPS challenged steroid treatments (“Betamethasone + LPS” and
“Triamcinolone + LPS”) and LPS only treatments (“LPS #1” and “LPS #2”). Error bars
represent standard deviation. * denotes a significant treatment effect. Pre-injection timepoint excluded as all were 0.
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Figure 2.6 Serum cortisol concentrations at designated time points comparing the saline
control to LPS challenged steroid treatments (“Betamethasone + LPS” and “Triamcinolone
+ LPS”) and LPS only treatments (“LPS #1” and “LPS #2”). Error bars represent standard
deviation. * denotes a significant treatment effect.
2.3.2

Corticosteroid-only Treatments
With respect to corticosteroid-only treatment, there were significant differences in

expression of IL-6 and PTGS1 (cyclooxygenase-1) with both corticosteroids when
compared to saline control. In regard to IL-6 expression, betamethasone was significantly
different from the control at 4, 6, and 24 hours and triamcinolone was significantly different
at 4, 6, 24, 48, and 72 hours (Figure 2.7). Betamethasone and triamcinolone were
significantly different from each other at the 48-hour time point. Additionally, with PTGS1
expression, betamethasone was significantly different from the control at 6, 9, and 12 hours
while triamcinolone was significantly different at 12, 24, and 144 hours (Figure 2.7).
Betamethasone and triamcinolone-associated expression of PTGS1 was not significantly
different.
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Figure 2.7 ln(RQ) values for IL-6 (top panel) and PTGS1 (lower panel) expression at
designated time points comparing the saline control to steroid-only treatments. Error bars
represent standard deviation. * denotes that the treatment is significantly different from the
control. # denotes that corticosteroids are significantly different from each other.

Cortisol was measured to quantify the suppressive effects of these corticosteroids on
its serum concentration. When comparing corticosteroid only treatments to saline control,
cortisol was significantly decreased by betamethasone at 2, 4, 6, 9, 12, 24, and 48 hours
and significantly decreased by triamcinolone at 2, 4, 6, 9, 12, 24, 48, 72, 96, and 120 hours
(Figure 2.8).
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Figure 2.8 Serum cortisol concentrations at designated time points comparing the saline
control to steroid-only treatments. Error bars represent standard deviation. * denotes that
the treatment is significantly different from the control. Values below the lower limit of
detection (0.20 μg/dL) were assigned the value of 0.
Serum drug quantification was performed on all pre-injection samples. At 14 days
after IA corticosteroid administration, two horses had serum triamcinolone concentrations
of 61.3 pg/mL and 31.8 pg/mL and one horse had a serum betamethasone concentration of
4.19 pg/mL (data not shown).
Evaluation of CBC data identified no significant treatment effects on white blood
cell, neutrophil, lymphocyte, or monocyte counts. Additionally, serum biochemistry panels
were unchanged (data not shown).

2.4

Discussion
While the control of excessive inflammation by intra-articular corticosteroids is well

documented [112, 113, 124, 154, 251-253], there is currently little information regarding
their effect on inflammatory gene expression and length of residual efficacy. We provide
the first report of intra-articular corticosteroids on systemic gene expression in an
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experimental inflammatory model. While one previous study utilized a model similar to
ours, inflammation was examined solely based on synovial fluid evaluation [154].
Supporting the previous findings in synovial fluid, our study demonstrates that
triamcinolone acetonide continues to display systemic anti-inflammatory effects 14 days
after administration based on a significant treatment effect on IL-6 and PTGS1
(cyclooxygenase-1) expression, lameness, SAA, and cortisol concentrations.
In regard to gene expression, there were significant findings with 2 of the genes
evaluated (IL-6 and PTGS1). Expression of interleukin 6 was evaluated in this study due
to its role in inflammation and the immune response. Interestingly, the exact proinflammatory or anti-inflammatory role that IL-6 plays is dependent upon the tissue or cell
type in which it is being expressed. Generally regarded as pro-inflammatory within muscles
following exercise, IL-6 regulates anti-inflammatory activities through mononuclear cell
recruitment and inhibition of T-cell apoptosis and regulatory T cell differentiation [254,
255]. Given that the mRNA utilized in this study originates from circulating white blood
cells, one would expect increases in IL-6 expression to represent its anti-inflammatory role.
Therefore, the lack of a decrease in mRNA expression when compared to LPS-only
injections suggests that both triamcinolone and betamethasone maintain an antiinflammatory effect 14 days following treatment. Importantly, a change in IL-6 expression
was the only indication of an anti-inflammatory effect seen in this study for betamethasone.
This is likely due to the fact that betamethasone reaches peak concentration sooner and has
a shorter half-life compared to triamcinolone [124, 148]. This is further supported by the
corticosteroid-only data for both IL-6 and PTGS1 expression as triamcinolone displays a
significant treatment effect for a longer period of time compared to betamethasone.
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Concurrent with the significant treatment effect of triamcinolone on IL-6, we
observed a similar effect on PTGS1 (prostaglandin endoperoxide synthase 1), the gene
encoding cyclooxygenase-1 (COX-1). COX-1 is a constitutively expressed enzyme that
plays an important role in the cyclooxygenase pathway, which is a main target in the
development of anti-inflammatory drugs [256]. COX-1 is responsible for the synthesis of
prostaglandins, eicosanoids derived from arachidonic acid that regulate inflammatory
processes such as pain, fever, and pro-inflammatory cytokine release. A significant
treatment effect was seen in this study in relation to PTGS1 expression, again indicating
that triamcinolone continues to exhibit anti-inflammatory effects 14 days after
administration since triamcinolone does not display a significant decrease in PTGS1
expression post-LPS injection. The decreased PTGS1 expression in betamethasone and
LPS-only treatments may cause a decrease in anti-inflammatory proteins, which in turn,
would likely increase pro-inflammatory protein concentrations.
One of the more important findings of the study was the residual anti-inflammatory
effect of triamcinolone on lameness, where it displayed a significant decrease in lameness
severity and longevity. This is an important finding given lameness is the primary cause of
decreased performance in equine athletes and joint injuries are one of the main reasons for
lameness [2, 4, 20]. Of the IA corticosteroids used to treat lameness associated with joint
disease, triamcinolone is reported to be the most common [106]. The Association of Racing
Commissioners International (ARCI) currently prohibits the use of IA corticosteroids less
than 14 days prior to racing [174] and the United States Equestrian Federation (USEF)
prohibits corticosteroid use less than 7 days prior to competition for competitive equestrian
disciplines [175]. Although treated horses may be sound and appear capable of competing,

42

it is possible that the corticosteroid is masking pain and inflammation, providing a
performance-enhancing benefit while posing a potential welfare risk. As such, withdrawal
regulations are put in place to avoid potential detrimental or performance-enhancing
effects, however, present findings suggest a residual effect of these drugs beyond these
time frames.
Further to the point of a residual anti-inflammatory effect of triamcinolone, serum
amyloid A concentrations were significantly lower in the horses 14 days after being treated
with this steroid. SAA is an acute-phase protein synthesized predominately by the liver that
rapidly increases in response to inflammation due to infection [257]. Because this protein
is pro-inflammatory, significantly lower production of SAA again demonstrates that
triamcinolone maintains residual anti-inflammatory effects. Interestingly, SAA1 gene
expression was also analyzed, however, there were no significant differences in expression
compared to pre-injection and control time points. This is likely due to the fact that most
circulating SAA is synthesized by the liver and the mRNA measured here comes from
whole blood.
Cortisol levels were measured as a marker of stress and as an indirect measure of
inflammation. This glucocorticoid regulates inflammation and immune function and its
anti-inflammatory effects occur from the downregulation of several pro-inflammatory
transcription factors, which then suppresses synthesis of inflammatory mediators such as
cytokines and prostaglandins [118-120]. Cortisol is produced by the adrenal glands and is
controlled by adrenocorticotropic hormone (ACTH), a hormone made by the adrenal gland,
and corticosteroids are known to decrease secretion of ACTH through the suppression of
the hypothalamic-pituitary-adrenal axis [121]. In this study, when comparing the
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corticosteroid-only treatments to each other, triamcinolone suppressed cortisol levels for a
significantly longer period of time compared to betamethasone. This is consistent with the
fact that triamcinolone has a longer half-life compared to betamethasone [124, 148]. As
such, these residual effects of corticosteroid administration on cortisol production may lead
to an inability of the horse to respond to a stressful event or infection, especially if more
than one joint is injected, as is common in equine athletes.
To better understand serum concentrations of residual corticosteroids 14 days after
the administration of LPS, serum samples were subject to analysis by liquid
chromatography tandem mass spectrometry. The findings revealed detection of
triamcinolone in two horses and betamethasone in one horse 14 days after administration.
Although the corticosteroids used here were given within accordance of ARCI guidelines,
the detection of the corticosteroids 14 days after administration is of concern since no trace
of corticosteroids is currently allowed on the day of racing. It is also important to note that
blood concentrations are not completely indicative of drug concentrations in the joint as
steroids are detectable in the blood for a much shorter timeframe compared to synovial
fluid [124, 168].
2.5

Limitations

The main limitation of this study is that the acute synovitis model used is not
representative of joint disease since the model induces significant inflammation whereas
joint disease is more of a low-grade, chronic condition. However, due to the severity of
this model, the findings presented here are even more striking given that there were
significant treatment effects on mRNA expression, lameness, SAA, and cortisol
concentration. If the findings presented here are extrapolated to a real-world situation
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where a horse has low-grade joint disease, corticosteroid treatment is likely to have an even
more substantial effect. It is also possible that betamethasone may present similar antiinflammatory effects as triamcinolone in a real-world diseased joint. Another limitation of
the study was the absence of exercise as most equine athletes return to training days after
IA corticosteroid administration. It has been shown that exercise affects inflammatory
cytokine gene expression in horses [240, 241], so it is uncertain how exercise would have
affected mRNA response in this model combined with IA corticosteroids. Regardless, this
model likely has utility to further test corticosteroids in other populations of horses or to
test the growing repertoire of biological treatment modalities that are available for joint
inflammation.

2.6

Future Directions
This study provides a means to determine the potential timeframe for the effects of

these drugs on the inflammatory response in horses in training and racing and in the future,
this information and experimental model could be used to further refine regulatory
withdrawal guidelines for intra-articular corticosteroids. Additionally, with a main
limitation in this study being that horses were not exercised, an important study for the
future may involve a similar experimental design with an exercise element in order to
assess the effect of the combination of exercise and intra-articular corticosteroid
administration on mRNA expression and cortisol concentrations. Finally, this model can
also be utilized for ortho-biologics to test other treatments for joint disorders.

2.7

Conclusion
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Overall, this work has advanced our knowledge on the effects of intra-articular
corticosteroids. The findings from this study suggest that the commonly used
corticosteroid, triamcinolone acetonide, has residual anti-inflammatory effects two weeks
after administration. Within the context of current racing and competition requirements,
this would suggest that 14 days may not be a long enough period if the concern is that the
drug may maintain performance enhancing effects via its anti-inflammatory properties.
Importantly, findings from this project demonstrate that the administration of intraarticular corticosteroids are not without risk, as evidenced by the significant effects on
serum cortisol, and, as such, the benefits of their administration should be weighed against
those risks.
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APPENDIX

APPENDIX 1. Manufacturers’ Addresses
a.

BetaVet, American Regent Inc, Shirley, NY, USA

b.

Kenalog, Bristol-Myers Squibb Company, New Brunswick, NJ,
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